Three generations of ongoing controversies concerning the use of short acting beta-agonist therapy in asthma: A review

Journal of Asthma

Volumn 45, Issue 1, 2008, Pages 9-18

  Jalba, Mihai Sergiu ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

Adrenergic; Adrenergic beta agonists; Albuterol enantiomers; Asthma; Beta; Genotype; Receptors

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FENOTEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; LEVALBUTEROL; PREDNISONE; SALBUTAMOL; SHORT ACTING DRUG;

ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CODON; CORTICOSTEROID THERAPY; DISEASE CONTROL; DRUG BINDING SITE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MISUSE; DRUG USE; DRUG WITHDRAWAL; ENANTIOMER; GENOTYPE; HUMAN; INFLAMMATION; LONG TERM EXPOSURE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; REVIEW; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA; TIME FACTORS;

EID: 38949182970     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900701495512     Document Type: Review

References (79)

1. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. BMJ 1968; 1:335-339.
2. Bremner P, Siebers R, Crane J, Beasley R, Burgess C. Partial versus full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol. Chest 1996; 109:957-962.
3. Stolley PD. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis. 1972; 105:883-890.
4. Stolley PD, Schinnar R. Association between asthma mortality and isoproterenol aerosols: a review. Prev Med. 1978; 7:519-538.
5. Beasley R. A historical perspective of the New Zealand asthma mortality epidemics. J Allergy Clin Immunol. 2006; 117:225-228.
6. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, Ball M, Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case control study. Lancet 1989; 1:917-922.
7. Sears MR. Changing patterns in asthma morbidity and mortality. J Investig Allergol Clin Immunol. 1995; 5:66-72.
8. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992; 32:501-506.
9. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol. 1996; 144:1161-1169.
10. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000; 343:332-336.
11. Barnes PJ. Rebuttal by Dr. Barnes. Am J Respir Crit Care Med. 2006; 174(9):974.
12. Beasley R, Pearce N, Crane J, Burgess C. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol. 1999; 104(2 Pt 2):S18-S30.
13. Sears MR, Taylor DR. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. 1994; 11:259-283.
14. Chapman KR, Kesten S, Szalai JP. Regular versus as-needed inhaled salbutamol in asthma control. Lancet 1994; 343:1379-1382.
15. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, Lazarus SC, Lemanske RF, Martin RJ, Peters SP, Sorkness C, Szefler SJ. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med. 1996; 335:841-847.
16. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004; 140:802-813.
17. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med. 2003; 2:287-297.
18. Walle UK, Pesola GR, Walle T. Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol. 1993; 35:413-418.
19. Eaton EA, Walle UK, Wilson HM, Aberg G, Walle T. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol. 1996; 41:201-206.
20. Dhand R, Goode M, Reid R, Fink JB, Fahey PJ, Tobin MJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med. 1999; 160:1136-1141.
21. Nowak R. Single-isomer levalbuterol: a review of the acute data. Curr Allergy Asthma Rep. 2003; 3:172-178.
22. Agrawal DK, Ariyarathna K, Kelbe PW. (S)-Albuterol activates proconstrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol. 2004; 113:503-510.
23. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther. 1998; 11:1-6.
24. Volcheck GW, Kelkar P, Bartemes KR, Gleich GJ, Kita H. Effects of (R)- and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005; 35:1341-1346.
25. Page CP, Morley J. Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol. 1999; 104(2 Pt 2):S31-S41.
26. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes. Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004; 113(1):101-108.
27. Johnson M. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol. 2002; 110:S282-S290.
28. Mitra S, Ugur M, Ugur O. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol. 1998; 53:347-354.
29. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle. J Allergy Clin Immunol. 2005; 116:65-72.
30. Ameredes BT, Calhoun WJ. Rebuttal by Drs. Ameredes and Calhoun. Am J Respir Crit Care Med. 2006; 174:972-974.
31. Agrawal DK, Kelbe PW. (S)-Albuterol binds to intracellular organelles and proteins in human airway smooth muscle cells. Am J Respir Crit Care Med. 2004; 169:A310.[abstract]
32. 3H](S)-Albuterol in Human Airway Smooth Muscle Cells. Proc Am Thorac Soc. 2006 April; 3:A467.[abstract]
33. Chorley BN, Li Y, Fang S, Park JA, Adler KB. (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS. Am J Respir Cell Mol Biol. 2006; 34:119-127.
34. Kuo A, Craig TJ. A retrospective study of risk factors for repeated admissions for asthma in a rural/suburban university hospital. J Am Osteopath Assoc. 2001; 101(5 Suppl):S14-S17.
35. Hakonarson H, Maskeri N, Carter C, Hodinka RL, Campbell D, Grunstein MM. Mechanism of rhinovirus-induced changes in airway smooth muscle responsiveness. J Clin Invest. 1998; 102:1732-1741.
36. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003; 139(5 Pt 1):359-370.
37. Lehmann PA, Rodrigues de Miranda JF, Ariens EJ. Stereoselectivity and affinity in molecular pharmacology. Prog Drug Res. 1976; (20):101-142.
38. Jalba MS. Eudismic Ratio and Enantiomeric Purity of the Albuterol Distomer. J Allergy Clin Immunol. 2004; 114:990-991.
39. Vakily M, Mehvar R, Brocks D. Stereoselective pharmacokinetics and pharmacodynamics of anti-asthma agents. Ann Pharmacother. 2002; 36:693-701.
40. Perrin-Fayolle M, Blum PS, Morley J, Grosclaude M, Chambe MT. Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Clin Rev Allergy Immunol. 1996 Spring; 14:139-147.
41. Cockcroft DW, Swystun VA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997; 52:845-848.
42. Nelson HS, Bensch G, Pleskow WW. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998; 102(6 Pt 1):943-952.
43. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol. 1999; 103(4):615-621.
44. Cockcroft DW, Davis BE, Swystun VA, Marciniuk DD. Tolerance to the bronchoprotective effect of beta2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol. 1999; 103:1049-1053.
45. Ramsay CM, Cowan J, Flannery E, McLachlan C, Taylor DR. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol. 1999; 55:353-359.
46. Handley DA, Tinkelman D, Noonan M, Rollins TE, Snider ME, Caron J. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37:319-327.
47. Lötvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol. 2001; 108:726-731.
48. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA; Levalbuterol Pediatric Study Group. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol. 2001; 108:938-945.
49. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 2003; 143:731-736.
50. Nowak RM, Emerman CL, Schaefer K, Disantostefano RL, Vaickus L, Roach JM. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med. 2004; 22:29-36.
51. Sjosward KN, Hmani M, Davidsson A, Soderkvist P, Schmekel B. Single-isomer R-salbutamol is not superior to racemate regarding protection for bronchial hyperresponsiveness. Respir Med. 2004; 98:990-999.
52. Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21:415-419.
53. Qureshi F, Zaritsky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med. 2005; 46:29-36.
54. Ralston ME, Euwema MS, Knecht KR, Ziolkowski TJ, Coakley TA, Cline SM. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med. 2005; 29:29-35.
55. Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 2005; 23:842-847.
56. Skoner DP, Greos LS, Kim KT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pulmonol. 2005; 40:477-486.
57. Nowak R, Emerman C, Hanrahan JP, Parsey MV, Hanania NA, Claus R, Schaefer K, Baumgartner RA; XOPENEX Acute Severe Asthma Study Group. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 2006; 24:259-267.
58. Berger WE, Milgrom H, Skoner DP, Tripp K, Parsey MV, Baumgartner RA; Xopenex Pediatric Asthma Group. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. Curr Med Res Opin. 2006; 22:1217-26.
59. Jantikar A, Brashier B, Maganji M, Raghupathy A, Mahadik P, Gokhale P, Gogtay J, Salvi S. Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study. Respir Med. 2007; 101:845-9. Epub 2007 Feb 1.
60. Ameredes BT, Calhoun WJ. (R)-albuterol for asthma: Pro[a.k.a (S)-albuterol for asthma: Con] Am J Respir Crit Care Med. 2006; 174:965-969.
61. Barnes, PJ. Treatment with (R)-albuterol has no advantage over racemic albuterol. Am J Respir Crit Care Med. 2006; 174(9):969-972.
62. Milgrom H. Levosalbutamol in the treatment of asthma. Expert Opin Pharmacother. 2006; 7:1659-1668.
63. Krishnan JA, Riekert KA, McCoy JV, Stewart DY, Schmidt S, Chanmugam A, Hill P, Rand CS. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med. 2004; 170:1281-1285. Epub 2004 Sep 16.
64. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest. 2003; 112:619-626.
65. Johnson M. Molecular Mechanisms of β2-adrenergic receptor function, response and regulation. J Allergy Clin Immunol. 2006; 117:18-24.
66. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000; 162:75-80.
67. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512.
68. Israel E. Genetics and the variability of treatment response in asthma. J Allergy Clin Immunol. 2005; 115(4 Suppl):S532-S538.
69. Cho SH, Oh SY, Bahn JW, Choi JY, Chang YS, Kim YK, Min KU, Kim YY. Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene. Clin Exp Allergy 2005; 35:1162-1167.
70. Taylor DR, Epton MJ, Kennedy MA, Smith AD, Iles S, Miller AL, Littlejohn MD, Cowan JO, Hewitt T, Swanney MP, Brassett KP, Herbison GP. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med. 2005; 172:700-703. Epub 2005 Jun 23.
71. Strauss L, Hejal R, Galan G, Dixon L, McFadden ER Jr. Observations on the effects of aerosolized albuterol in acute asthma. Am J Respir Crit Care Med. 1997; 155:454-458.
72. Song P, Milanese M, Crimi E, Bruzzone S, Zocchi E, Rehder K, Brusasco V. G(s) protein dysfunction in allergen-challenged human isolated passively sensitized bronchi. Am J Physiol Lung Cell Mol Physiol. 2000; 279:L209-L215.
73. Shore SA, Drazen JM. Beta-agonists and asthma: too much of a good thing? J Clin Invest. 2003; 112:495-497.
74. Tepe NM, Liggett SB. Functional receptor coupling to Gi is a mechanism of agonist-promoted desensitization of the beta2-adrenergic receptor. J Recept Signal Transduct Res. 2000; 20:75-85.
75. Eisner MD, Lieu TA, Chi F, Capra AM, Mendoza GR, Selby JV, Blanc PD. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J. 2001; 17:233-240.
76. Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JP. Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol. 2005; 115:963-972.
77. Swift SM, Schwarb MR, Mihlbachler KA, Liggett SB. Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007; 36:236-243.
78. Lowe KC. Xopenex: The beginning of a new trend in pharmaceutics or all hype ? PharmaNote 2005; 20(8):1-8.
79. Fenech A, Hall IP. Pharmacogenetics of asthma. Br J Clin Pharmacol. 2002; 53:3-15.